rhil-7-hyfc
Recombinant proteinexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2018 (NCT03687957)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Merkel Cell · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- COVID-19 · Phase 1
- Glioma · Phase 1/Phase 2
- Leukoencephalopathy, Progressive Multifocal · Early Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Melanoma · Phase 1/Phase 2
- Multiple Myeloma · Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- SARS-CoV-2 · Phase 1
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Interleukin-7AGONIST
Interleukin-7 agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07200089 | Phase 1 | Jan 31, 2026 | NeoImmuneTech, Inc., Washington University in St. Louis |
| NCT07052305 | Phase 1 | Oct 31, 2025 | NeoImmuneTech, Inc., Washington University in St. Louis |
| NCT04781309 | Early Phase 1 (Phase 1) | May 5, 2021 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT04498325 | Phase 1 | Dec 31, 2020 | NeoImmuneTech, Inc., Washington University in St. Louis |
| NCT04332653 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2020 | NeoImmuneTech, Inc. |
| NCT03901573 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2019 | NeoImmuneTech, Inc., The Cleveland Clinic, University of Washington |
| NCT03687957 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2018 | Washington University in St. Louis |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeoImmuneTech, Inc. | For profit | 5 | 2 | 2 | 2019 |
| Washington University in St. Louis | Academic/Hospital | 4 | 4 | 2 | 2018 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2021 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1